The Prescribing Data Restriction Program - Critical Assessment and Best Practices

Since the mid-1990s, pharma companies have devised their sales and marketing strategies based on Rx data.

However, with the introduction of the AMA's Prescribing Data Restriction Program (PDRP) opt-out program in July 2006, pharma companies need to evaluate the impact of PDRP violation, mediate their PDRP compliance strategies, and revisit their existing Sales Force Effectiveness (SFE) practices. With the introduction of the PDRP, the use of physician Rx data by pharmaceutical companies will never be the same again. The PDRP prohibits access to physician-level Rx data, which directly impacts First Line Managers, Sales Representatives, and anyone else that accesses or distributes physician Rx data.

Arrowhead Publishers’ report The Prescribing Data Restriction Program: Critical Assessment and Best Practices estimates the impact of PDRP violations, analyzes the use of Rx data, gauges awareness in the marketplace and benchmarks the best practices towards PDRP compliance.

Key features of this report:

> Best practices towards PDRP compliance

> Outline of the practical implications of the PDRP

> Industry perceptions of the PDRP (survey research)

Reasons to purchase this report:

> Understand what other pharma companies are doing to comply with the PDRP.

> Learn the financial rewards associated with successful PDRP compliance strategies

> Gain a better understanding of the program and its implications for the pharma industry

> Understand the areas of impact of PDRP violations, and inefficient PDRP compliance strategies

Publication Date: September 10, 2006

Table of Contents

Price
Single User PDF $1500.00
Site Licence PDF $3000.00
Corporate Wide Licence PDF $4500.00